IRF6 and plasma cell myeloma: Indeed, we observed that a small molecule proteasome inhibitor bortezomib used for multiple myeloma treatment [32] upregulates both IRF6 and its target BLNK in ErbB2-positive breast cancer cells BT474 (Fig. 7A, B).